This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A FURTHER QUESTIONING OF THE ALLEGED NONSPIROCHETICIDAL PROPERTIES OF THE PENTAVALENT ARSENICAL IN TREATMENT OF HUMAN SYPHILIS, WITH A SUGGESTION REGARDING ITS READOPTION INTO THE CURRICULUM OF THERAPY FOR EARLY SYPHILIS

H. SUTHERLAND CAMPBELL, M.D.

Arch Derm Syphilol. 1936;34(4):582-589.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The pentavalent arsenical compound tryparsamide, as synthesized by Jacobs and Heidelberger, was produced at the Rockefeller Institute in 1917. It possesses the following structure: the sodium salt of normo-phenylglycinamide-para-arsonic acid, containing 25.32 per cent arsenic in pentavalent form. It is a white crystalline powder, colorless and odorless in water, in which it is readily soluble. Early experimental inquiry demonstrated that the tolerance of different animal species for it varied widely, that the toxic effects were confined to doses close to the minimal lethal dose, which was distinctly high, and that recovery from a sublethal dose was peculiarly rapid and complete. Several persons reported most favorable results from its use in treatment of trypanosomiasis in man. This work was followed by a report in 1919 by Brown and Pearce, who studied a large series of animals that were infected with various strains of trypanosomes and spirochetes. They noticed . . . [Full Text PDF of this Article]

Author Affiliations
LOS ANGELES

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?